Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Cash (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Change in Cash for 5 consecutive years, with -$9.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 110.74% year-over-year to -$9.3 million, compared with a TTM value of -$18.0 million through Dec 2025, down 123.78%, and an annual FY2025 reading of -$18.0 million, down 123.78% over the prior year.
  • Change in Cash was -$9.3 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from -$17.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $86.2 million in Q4 2024 and bottomed at -$67.7 million in Q4 2021.
  • Average Change in Cash over 5 years is $2.6 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Change in Cash plummeted 1116.6% in 2022, then surged 973.05% in 2024.
  • Year by year, Change in Cash stood at -$67.7 million in 2021, then grew by 21.66% to -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then soared by 973.05% to $86.2 million in 2024, then tumbled by 110.74% to -$9.3 million in 2025.
  • Business Quant data shows Change in Cash for KNSA at -$9.3 million in Q4 2025, -$17.2 million in Q3 2025, and $34.9 million in Q2 2025.